Travere Therapeutics (TVTX) Tops Q2 EPS by 16c

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.14), $0.16 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $99.25 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook